Heart Attack - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 41 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Heart Attack - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Heart Attack - Pipeline Review, H2 2014', provides an overview of the Heart Attack's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Heart Attack, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Heart Attack and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Heart Attack
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Heart Attack and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Heart Attack products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Heart Attack pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Heart Attack
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Heart Attack pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Heart Attack Overview 6
Therapeutics Development 7
Pipeline Products for Heart Attack - Overview 7
Pipeline Products for Heart Attack - Comparative Analysis 8
Heart Attack - Therapeutics under Development by Companies 9
Heart Attack - Therapeutics under Investigation by Universities/Institutes 10
Heart Attack - Pipeline Products Glance 11
Early Stage Products 11
Heart Attack - Products under Development by Companies 12
Heart Attack - Products under Investigation by Universities/Institutes 13
Heart Attack - Companies Involved in Therapeutics Development 14
Lacer, S.A. 14
Aronora, LLC 15
Lanthio Pharma B.V. 16
Heart Attack - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 25
AB-002 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
LA-8045 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Cell Therapy to Inhibit Myosin for Cardiovascular Disorders - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NVX-308 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
LWnt-3a - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit PDE5 for Ischemia Reperfusion Injury - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Synthetic Peptides to Activate Complement C3 for Immunology, Cardiovascular and CNS Disorders - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Heart Attack - Dormant Projects 33
Heart Attack - Product Development Milestones 34
Featured News & Press Releases 34
Jul 15, 2014: Thymosin s4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice 34
May 27, 2014: NeoStem Announces Grant of Two U.S. Patents for CD34 Cell Program 34
May 08, 2014: FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients 35
Dec 26, 2013: AstraZeneca and Shionogi settle arbitration and extend licence agreement for CRESTOR 35
Dec 23, 2013: Heart Disease Therapy Cleared for Phase 2 Clinical Trial to be Funded by Stem Cell Agency 36
Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack 36
Aug 06, 2013: Athersys Announces Grant to Support Clinical Advancement of Its MultiStem Regenerative Medicine Program for Heart Attack Patients 37
Mar 11, 2013: Roche's Inclacumab Shows Efficacy In Reducing Heart Damages During Artery Clearing Angioplasty Procedures 38
Nov 29, 2012: AstraZeneca Wins Chinese Approval For New Heart Drug Brilinta 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products under Development for Heart Attack, H2 2014 7
Number of Products under Development for Heart Attack - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Products under Investigation by Universities/Institutes, H2 2014 13
Heart Attack - Pipeline by Lacer, S.A., H2 2014 14
Heart Attack - Pipeline by Aronora, LLC, H2 2014 15
Heart Attack - Pipeline by Lanthio Pharma B.V., H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 24
Heart Attack - Dormant Projects, H2 2014 33